Sanofi-Aventis has bought development and marketing rights to Taiho Pharmaceutical Co. Ltd.'s proprietary oral, pyrimidine fluoride derived oral anticancer agent, S-1.
Sanofi-Aventis is paying Taiho $360 million for the rights to develop and commercialize the drug, which is already on Phase III clinical stage in Europe and the US.
The marketing rights will be worldwide, except in Japan, where S-1 has already marketed since 1999, as well as in certian Asian countries.
More details of the deal from Sanofi-Aventis' press release (pdf file) or see report from Trading Markets.
.jpg)
send information of s 1
Posted by: dr unmesh | October 27, 2007 10:42 AM | Permalink to Comment